MARKET

PPBT

PPBT

Purple Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
-0.270
-6.04%
After Hours: 4.140 -0.06 -1.43% 19:58 01/27 EST
OPEN
4.300
PREV CLOSE
4.470
HIGH
4.330
LOW
4.080
VOLUME
771.78K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
2.200
MARKET CAP
72.28M
P/E (TTM)
-0.3333
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 01/20 12:32
Purple Biotech to Present at the B. Riley Oncology Investor Conference
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the Purple...
GlobeNewswire · 01/18 12:41
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech
GlobeNewswire · 01/04 14:40
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
GlobeNewswire · 01/04 14:40
Kitov Pharma changes name to Purple Biotech
Kitov Pharma ([[KTOV]] -0.2%) announces corporate name change from Kitov Pharma to Purple Biotech Ltd.The name change will be effective for trading purposes on the Tel Aviv Stock Exchange and NASDAQ as
Seekingalpha · 12/10/2020 16:36
Kitov Announces Name Change To Purple Biotech Ltd.
TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the "Company") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and
Benzinga · 12/10/2020 13:20
Kitov Announces Name Change to Purple Biotech Ltd.
New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies
GlobeNewswire · 12/10/2020 13:17
Kitov Pharma to Participate in November Investor Conferences
Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that management will present at the H.C. Wainwright 6 Annual Israel Conference and will participate in one-on-one meetings at the Jefferies Virtual London Healthcare Conference.
GlobeNewswire · 11/11/2020 12:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PPBT. Analyze the recent business situations of Purple Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PPBT stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 435.91K
% Owned: 2.53%
Shares Outstanding: 17.21M
TypeInstitutionsShares
Increased
2
11.05K
New
26
-60.66K
Decreased
3
26.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.27%
Pharmaceuticals & Medical Research
-3.25%
Key Executives
Chairman/Director
John Waymack
Chief Executive Officer/Director
Itzhak Israel
Chief Financial Officer/Director
Simcha Rock
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Hadas Reuveni
Independent Director
Ido Agmon
Non-Executive Director
Alain Zeitoun
Independent Director
Steven Steinberg
Independent Director
Philip Serlin
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
  • Dividends
  • Splits
  • Insider Activity
No Data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Webull offers kinds of Purple Biotech Ltd stock information, including NASDAQ:PPBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PPBT stock methods without spending real money on the virtual paper trading platform.